UnitedHealth Group (UNH) director boosts holdings with 43 dividend-equivalent shares

Rhea-AI Filing Summary

UnitedHealth Group director John H. Noseworthy, M.D. reported a small increase in his holdings of UnitedHealth Group common stock. On 12/16/2025, he acquired 43 shares at a price of $0, described as dividend equivalents paid on vested deferred stock units. These dividend equivalents are immediately vested and follow the same terms as the underlying deferred stock units. Following this transaction, he beneficially owns 6,736 shares of UnitedHealth Group common stock in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Noseworthy John H

(Last) (First) (Middle)

C/O UNITEDHEALTH GROUP INCORPORATED

1 HEALTH DRIVE

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITEDHEALTH GROUP INC [ UNH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		A		43(1)	A	$0	6,736	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents dividend equivalents paid on vested deferred stock units. The dividend equivalents are immediately vested and are subject to the same terms as the underlying deferred stock units.

Remarks:

	Faraz A. Choudhry, Attorney-in-Fact for John H. Noseworthy M.D.	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UnitedHealth Group (UNH) report for John H. Noseworthy?

UnitedHealth Group reported that director John H. Noseworthy, M.D. acquired 43 shares of common stock on 12/16/2025 through dividend equivalents on vested deferred stock units.

At what price were the new UnitedHealth Group (UNH) shares acquired by the director?

The 43 shares reported for John H. Noseworthy, M.D. were acquired at a price of $0, reflecting dividend equivalents rather than an open-market purchase.

How many UnitedHealth Group (UNH) shares does John H. Noseworthy own after this transaction?

After the reported transaction, John H. Noseworthy, M.D. beneficially owns 6,736 shares of UnitedHealth Group common stock in direct ownership.

What are dividend equivalents on UnitedHealth Group (UNH) deferred stock units?

The filing states that the 43 acquired shares represent dividend equivalents paid on vested deferred stock units. These dividend equivalents are immediately vested and are subject to the same terms as the underlying deferred stock units.

Is John H. Noseworthy a director or officer of UnitedHealth Group (UNH)?

The report identifies John H. Noseworthy, M.D. as a Director of UnitedHealth Group Inc.

Was the UnitedHealth Group (UNH) insider transaction filed for one person or multiple people?

The form was indicated as filed by one reporting person, covering only the holdings of John H. Noseworthy, M.D.